---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-029787"
form_type: "8-K"
ticker: "CHRS"
cik: "0001512762"
company_name: "Coherus Oncology, Inc."
filed_at: "2022-02-07T23:59:59+00:00"
generated_at: "2026-06-27T10:38:16.361911+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Coherus appoints Dr. Lee Newcomer to board; Dr. James Healy resigns

## Summary
- Appointed Dr. Lee Newcomer to Board effective Feb 2; receives option for 54k shares plus $50k annual retainer.
- Newcomer is former UnitedHealth CMO, brings oncology and payer expertise to board.
- Director James Healy resigned Feb 4; departure not due to any disagreement.
- Mark Stolper reclassified from Class III to Class II to equalize board class sizes.
- Board expanded to 7 members; now 2 directors per class.

## SEC filing metadata
- accession: 0001193125-22-029787
- form_type: 8-K
- ticker: CHRS
- cik: 0001512762
- company_name: Coherus Oncology, Inc.
- filed_at: 2022-02-07T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/d298250d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-029787
- JSON: https://secwatch.observer/filing/0001193125-22-029787.json
- Plain text: https://secwatch.observer/filing/0001193125-22-029787.txt

## Key facts
- Executive change
  Lee N. Newcomer was appointed as Director at Coherus Oncology, Inc..
  - Action: appointed
  - Role: Director
  source text: On February 2, 2022, upon the recommendation of its Nominating and Corporate Governance Committee (the “Nominating Committee”), the Board of Directors (the “Board”) of Coherus BioSciences, Inc. (the “Company”) increased the size of the Board from six directors to seven directors and appointed Dr. Lee N. Newcomer to fill the vacancy created by such increase.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm
- Executive change
  James I. Healy resigned as Director at Coherus Oncology, Inc..
  - Action: resigned
  - Role: Director
  source text: On February 4, 2022, James I. Healy, M.D., Ph.D. resigned from the Board of the Company, effective immediately upon notice of his resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1512762/000119312522029787/0001193125-22-029787-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.